Home From Drew Altman

From Drew Altman

Drew Altman is president and chief executive officer of KFF, a position he has held for more than 30 years since founding the modern-day KFF organization in the 1990s. He is a leading expert on national health policy issues and an innovator in health journalism and the nonprofit field.

View full bio | Read Dr. Altman's Beyond the Data columns

Photo of Drew Altman

President’s Message

“KFF is an independent source of health policy research, polling, and journalism. We have four major program areas: KFF Policy; KFF Polling; KFF Health News (formerly Kaiser Health News); and KFF Social Impact Media, which conducts specialized public health information campaigns. Learn more about the organization. 

What’s unique about KFF, however, can’t be found in any description of our programs because we’re more than a sum of our parts. KFF is a one-of-a-kind information organization. Not a policy research organization. Not a polling organization. And not a news organization. But rather, a unique combination of all three. That’s the vision behind KFF, and it's this combination that allows us to leverage our combined expertise and assets to play our national role on health policy.” Read more

Beyond the Data

In his “Beyond the Data” columns, Drew Altman discusses what the data, polls, and journalism produced by KFF mean for policy and for people.

Medicare Beneficiaries Are Not Luddites

In a new column, President and CEO Dr. Drew Altman discusses new KFF survey data that shows that a surprising share of older adults with Medicare are using health tech regularly, and a solid majority support many of CMS’ goals to make it more widely available. But there are also big income gaps in the use of health tech, and concerns about AI, privacy, and other barriers to rapid and more widespread adoption. “Apparently… a lot of Medicare beneficiaries—but not all beneficiaries equally—are ready for more health tech, and have become tech savvy to survive,” Altman writes.

View All Beyond the Data Columns

View the Latest: From Drew Altman

Filter

List Grid

51 - 60 of 328 Results

  • Persistent Vaccine Myths

    From Drew Altman

    With news that the country has now vaccinated half of its population with at least one dose, This Drew Altman Axios column highlights the persistent COVID-19 vaccine myths that are believed by a substantial portion of the unvaccinated population and discusses the options to address vaccine misinformation.

  • Corporate Leaders Are Getting Bullish On Government Action On Health Care Costs

    From Drew Altman

    In this Axios column, Drew Altman explores whether the long struggle with rising health costs has caused the tide to turn in corporate leaders’ attitudes towards government involvement in controlling health spending and whether it is part of a larger shift in comfort with government action to solve problems.

  • Where To Start To Build Vaccine Confidence

    From Drew Altman

    In this Axios column Drew Altman writes about the recent attention to Republican vaccine resisters. “Republicans and rural Americans are among the most resistant vaccine holdouts and some strategies are emerging to reach them." But “far from all Republicans are resisters” and “the bigger and quicker payoff will come from prioritizing the more moveable group of 'wait and see' Americans.”

  • Vaccine Confidence Isn’t The Main Obstacle To Reaching Herd Immunity

    From Drew Altman

    In this Axios column, Drew Altman paints a more optimistic picture of the prospects for getting to herd immunity as vaccine confidence grows, but underscores the urgency of building vaccine confidence in Black and Latino communities where barriers to access and good information are obstacles to getting vaccinated.

  • Seeing Others Vaccinated May Be The Best Cure For Vaccine Hesitancy

    From Drew Altman

    In his latest Axios column, Drew Altman shows why vaccine hesitancy will naturally decrease as more and more people see their family members and friends vaccinated without adverse consequences. It’s a hopeful sign about vaccine hesitancy, and should help free up resources to focus on the remaining vaccine hesitant.